Celularity Inc. Class A CELU 深 沪
等待开盘 04-02 09:30:00 美东时间
1.31
-0.020
-1.50%
华盛通- 最 高1.33
- 今 开1.33
- 成交量 5520股
- 最 低 1.29
- 昨 收 1.33
- 总市值 3777.75万
- 52周最高 4.35
- 市盈率 静 --
- 换手率 0.02%
- 52周最低 1.01
- 委 比 -8.93%
- 总股本 2883.78万
- 历史最高 134.00
- 量 比 0.14
- 振 幅 3.01%
- 历史最低 1.0007
- 每 手 1
- 风险率 0.68%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Celularity Signs $35M Agreements For Its Placental-Derived Biomaterials Portfolio
Celularity Inc. (Nasdaq: CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company focused on longevity science, today announced that it has entered into definitive agreements establishing a
03-10 20:32
EXCLUSIVE: NexGel To Acquire Regenerative Biomaterial Portfolio From Celularity, Expects To Triple Revenue
NexGel to acquire Celularity biomaterial products, a deal expected to triple revenue to $35 million and make the company profitable.
03-10 20:30
Celularity Receives $12.2M In Net Cash Proceeds From Sale Of ~$126.3M Of Unused New Jersey NOLs And $1.9M Of Unused New Jersey R&D Tax Credits
Celularity Inc. (NASDAQ:CELU) ("Celularity"), a longevity-focused regenerative and cellular medicine company, today announced receipt of $12.2 Million in net cash proceeds from the sale of approximately $126.3 Million of
02-10 21:43
Celularity Files Prospectus For The Offering Of Up To 14.1M Shares Of Class A Common Stock
Celularity Inc. Up to 14,078,938 shares of Class A Common Stock Pursuant to this prospectus, the selling stockholders identified herein (the "Selling Stockholders") are offering on a resale basis an aggregate
01-01 05:19
FDA Issues Warning Letter To Celularity Over Interfyl Marketing Claims; Co Says No Impact On Manufacturing Or Shipments
On December 1, 2025, Celularity Inc., (the "Company") received a warning letter (the "Letter") from the U.S. Food and Drug Administration (the "FDA"). The Letter relates to the use of certain marketing material for
2025-12-06 05:36
Celularity Files For 6M Series A Convertible Preferred Stock, Raising Up To $6.67M In Private Placement With Warrants
Private Placement Transaction On October 24, 2025, Celularity Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with an institutional investor (the "Investor"), pursuant to
2025-10-28 21:40
Celularity Announces Publication Of Its Phase 2 Study On PDA-002 Demonstrating Safety And Efficacy In Treating Complex Diabetic Wounds
Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced the publication of its Phase 2 study titled "Human
2025-10-14 20:49
Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease
Celularity Inc. announced positive results from its Phase 2 study of PDA-002, a placenta-derived stem cell therapy, for treating diabetic foot ulcers (DFU) complicated by peripheral artery disease (PAD). The study, published in the International Wound Journal, demonstrated that PDA-002 achieved durable wound healing with just two intramuscular doses. The therapy showed higher wound closure rates compared to placebo, particularly in patients with ...
2025-10-14 12:45
美股大行评级 | 潜在涨幅577.08%！Veritone获D. Boral Capital升目标价至26美元，维持"买入"评级
今日重点评级关注：D. Boral Capital：维持Veritone"买入"评级，目标价从6美元升至26美元；Guggenheim：维持Dianthus Therapeutics"买入"评级，目标价从92美元升至100美元
2025-09-10 18:01
